• Home
  • About ISDB
    • What is ISDB?
    • Committee
    • Constitution
  • How to join
    • COI-forms
    • Criteria for membership
    • Application forms
  • Members
    • Bulletin index
    • Full members
    • Associated members
  • Publications
    • Newsletters
    • ISDB Publications
    • Press releases
    • Documents of interest
  • Campaigns
    • Working groups
    • Petitions
    • Future meetings
    • Past meetings
  • Intranet

ISDB – International Society of Drug Bulletins

International Society of Drug Bulletins

  • Home
  • About ISDB
    • What is ISDB?
    • Committee
    • Constitution
  • How to join
    • COI-forms
    • Criteria for membership
    • Application forms
  • Members
    • Bulletin index
    • Full members
    • Associated members
  • Publications
    • Newsletters
    • ISDB Publications
    • Press releases
    • Documents of interest
  • Campaigns
    • Working groups
    • Petitions
    • Future meetings
    • Past meetings
  • Intranet
  • Menu

Boletin Farmacos

March 5, 2010

Referent: Nuria Homedes
Address: 1100 North Stanton Suite 110  El Paso, Texas 79902
Phone: 915 585 6450
Email: nhomedes@utep.edu 
Website: www.boletinfarmacos.org/

Recent Publications

  • ISDB General Assembly Paris 2019
  • Newsletter ISDB 2019 vol. 32 nr. 1, March 2019
  • Cochrane’s sinking ship and conflicts of interest
  • Newsletter ISDB 2018 vol. 31 nr. 1, September 2018
  • Newsletter December 2017

Recent Campaigns

  • ISDB General Assembly Paris 2019
  • News from working groups: Clinical Study Reports?
  • News from working groups: Clinical Trials Group
  • A PRIME example of how EMA is pushing for accelerated market approvals, but at what cost for patients?
  • “Adaptive licensing” or “adaptive pathways”: Deregulation under the guise of earlier access

Contact

President
Dick Bijl
president@isdbweb.org

Webmaster
Uw Computerstudent
michael.wijnands@uwcomputerstudent.nl

Press releases

  • ISDB General Assembly Paris 2019
  • Cochrane’s sinking ship and conflicts of interest
  • No to EMA’s provision of confidential scientific advice to drug companies (November 2017)
  • Supplementary protection certificates (SPCs) delay access to affordable medicines (September 2017)
  • Proposed changes to EMA’s access to documents policy fall short on proactive disclosure (May 2017)

Newsletters

  • Newsletter ISDB 2019 vol. 32 nr. 1, March 2019
  • Newsletter ISDB 2018 vol. 31 nr. 1, September 2018
  • Newsletter December 2017
  • Newsletter November 2014
  • Newsletter March 2014

© 2019 ISDB – International Society of Drug Bulletins.